News

The company announced clinical trial results of the Phase 1 study of TH-302 in patients with advanced leukemias conducted at MD Anderson's Cancer Center in Houston, Texas.

Burrill will assist the company in evaluating strategic alternatives related to Gene Logic and its assets, which could include a sale of its US-based company, operations or its assets.

Partnership follows major contract win with large pharmaceutical company.

Framework agreement initiated with three Compugen-discovered peptides mutually selected for further development by BioLineRx.

The Society for Laboratory Automation and Screening (SLAS), a multi-disciplinary, non-profit scientific association spanning diverse industries and technology sectors, positions itself for the future with the recent addition of three newly elected members of the Board of Directors.

The assay is used in testing serum and plasma in the transfusion and transplantation community. The ongoing clinical data collection phase of the clinical trial is estimated to be completed within 4 – 6 weeks.

CEO Ellen Kullman and the company’s senior leaders detail the dynamic global growth strategy for continuing to deliver strong, sustainable results in 2012 and beyond.

Synergy Pharmaceuticals, Inc. announced that it has filed a lawsuit in New York State Supreme Court against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie.

The European commission has appointed Anne Glover as its first ever chief scientific adviser.

The approach offers an innovative scientific approach for designing optimized protein formulations, and reduces the need for extensive stability testing.